Bioventus Q2 2024 Adj. EPS $0.19 Beats $0.07 Estimate, Sales $151.217M Beat $137.595M Estimate
Portfolio Pulse from Benzinga Newsdesk
Bioventus (NASDAQ:BVS) reported Q2 2024 adjusted EPS of $0.19, significantly beating the analyst estimate of $0.07. The company also reported sales of $151.217 million, surpassing the estimate of $137.595 million. Both EPS and sales showed substantial year-over-year growth.
August 06, 2024 | 11:32 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Bioventus reported Q2 2024 adjusted EPS of $0.19, beating the analyst estimate of $0.07 by 171.43%. Sales were $151.217 million, surpassing the estimate of $137.595 million. Both metrics showed significant year-over-year growth.
The significant beat on both EPS and sales estimates, along with strong year-over-year growth, is likely to positively impact Bioventus' stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100